The Discngine Meetup returns for its 6th edition this October!
Our annual virtual event brings together drug discovery professionals from pharma, biotech, and computational sciences to exchange on current practices and evolving approaches. This year’s edition focuses on Large Language Models (LLMs) in Drug Discovery, exploring how these technologies are being applied today and what they can realistically bring to early research workflows. Expect a two-hour program featuring industry perspectives, use cases, and open discussion. The event is a great opportunity to discover how peers are approaching LLMs, what’s working, and where challenges remain.
Save the date and join the discussion on October 20th.
This summer, we will reveal a major update to Ideation Analytics, our platform for Structure-Activity Relationship (SAR) analysis and reporting in small-molecule discovery.
This milestone release introduces an enhanced user experience for more efficient SAR exploration, patent analysis, and report building, along with new capabilities for collaboration, sharing, and data management.
3decision - Discngine’s protein structure repository and analytics platform - now enables enhanced exploration of similar binding sites across all protein families, including in‑house and public data (PDB, AlphaFoldDB).
Scientists can benefit from its unique 3D pocket-based algorithm to identify potential off-targets and support idea generation for novel designs.
Across both events, you’ll have the opportunity to meet our team and discover Ideation Analytics, our platform supporting SAR analysis and reporting for small molecules.
If you’re attending either event, make sure to connect with us!
Why considering SAR alongside patent disclosures matters
SAR guides compound design, while patent data adds context on prior art, but they’re often reviewed separately. Our latest article explores how bringing them together supports clearer, more confident decisions and how our tool, Ideation Analytics, makes this possible.
In our latest article, our Biologics Solution Lead, Méliné Simsir, shares insights gathered from four antibody-focused events and outlines the main trends shaping modern antibody discovery.
TROP2 has emerged as a key oncology target, with companies increasingly investing in TROP2‑targeting ADCs.
As some of these approved ADCs move into earlier lines of treatment, novel structural insights into the TROP2 complex with clinical-stage ADCs are helping guide the design of next-generation therapies.
You’re receiving this message because you’ve either participated in one of Discngine’s events, subscribed via our website or opted in to receive updates, requested information from us - either in person, online, or through written communication, or your organization has licensed one of Discngine’s products or solutions.
-2.png?upscale=true&width=1120&upscale=true&name=image%20(1)-2.png)
-1.png?upscale=true&width=520&upscale=true&name=Antibody%20event%20insights%20blog%20post%20THUMBNAIL%20(1)-1.png)
